LCTX (Lineage Cell Therapeutics) FCF Margin % : -156.10% (As of Sep. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Lineage Cell Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lineage Cell Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was $-5.90 Mil. Lineage Cell Therapeutics's Revenue for the three months ended in Sep. 2024 was $3.78 Mil. Therefore, Lineage Cell Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was -156.10%.

As of today, Lineage Cell Therapeutics's current FCF Yield % is -20.12%.

The historical rank and industry rank for Lineage Cell Therapeutics's FCF Margin % or its related term are showing as below:

LCTX' s FCF Margin % Range Over the Past 10 Years
Min: -2563.65 Med: -1980 Max: 4.39
Current: -264.43

During the past 13 years, the highest FCF Margin % of Lineage Cell Therapeutics was 4.39%. The lowest was -2563.65%. And the median was -1980.00%.

LCTX's FCF Margin % is ranked worse than
58.09% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs LCTX: -264.43

Lineage Cell Therapeutics FCF Margin % Historical Data

The historical data trend for Lineage Cell Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics FCF Margin % Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-2,191.27

-2,563.65

-613.48

4.39

-326.89

Lineage Cell Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-415.41	-292.62	-403.12	-371.16	-156.10

Competitive Comparison of Lineage Cell Therapeutics's FCF Margin %

For the Biotechnology subindustry, Lineage Cell Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's FCF Margin % falls into.

Lineage Cell Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lineage Cell Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-29.24	/	8.945
	=	-326.89 %

Lineage Cell Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-5.899	/	3.779
	=	-156.10 %

Lineage Cell Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (AMEX:LCTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

LCTX:Israel BT3:Germany BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Executives

Jill Ann Howe	officer: Chief Financial Officer	C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Samuel George A. Iii	officer: General Counsel/Secretary	C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Michael H. Mulroy	director	1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Brian M Culley	director, officer: President and CEO	6725 MESA RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Don M Bailey	director	1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92607
Broadwood Partners Lp	10 percent owner	BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Anula Jayasuriya	director	5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Dipti Amin	director	C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Gary S. Hogge	officer: SVP,Clinical & Medical Affairs	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Angus C. Russell	director	C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kevin Leon Cook	officer: Chief Financial Officer	C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Alexandra Hernandez	officer: Sr Director Finance/Controller	C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Brandi Roberts	officer: CFO & SVP, Finance	12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Chase C. Leavitt	officer: General Counsel/Secretary	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Edward Wirth	officer: Chief Medical Officer	C/O INVIVO THERAPEUTICS HOLDING CORP., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142